A federal appeals court has upheld certification of a class of consumers and insurance companies alleging that they were forced to pay higher prices for prescription heartburn drug Nexium in violation of state antitrust laws.

The effect of Wednesday’s ruling by the U.S. Court of Appeals for the First Circuit is unclear, given that a federal jury on Dec. 5 rendered a defense verdict in the case.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]